keyword
https://read.qxmd.com/read/38427280/a-phase-ii-study-of-folfiri-plus-ziv-aflibercept-after-trifluridine-tipiracil-plus-bevacizumab-in-patients-with-metastatic-colorectal-cancer-wjog-11018g
#1
JOURNAL ARTICLE
Toshihiko Matsumoto, Yoshiyuki Yamamoto, Masahito Kotaka, Toshiki Masuishi, Yasushi Tsuji, Hirokazu Shoji, Kenro Hirata, Takao Tsuduki, Akitaka Makiyama, Naoki Izawa, Naoki Takahashi, Masahiro Tsuda, Hisateru Yasui, Takashi Ohta, Yosuke Kito, Satoshi Otsu, Shuichi Hironaka, Kentaro Yamazaki, Narikazu Boku, Ichinosuke Hyodo, Kenichi Yoshimura, Kei Muro
BACKGROUND: Non-inferiority of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) to irinotecan/fluoropyrimidine plus BEV in metastatic colorectal cancer was investigated in the phase III TRUSTY study, and we conducted a phase II study of FOLFIRI (5-FU+leucovorin+irinotecan) plus zib-aflibercept (AFL) after FTD/TPI plus BEV. However, the TRUSTY study failed during the recruitment of our patients. OBJECTIVE: We present the findings of a phase II study on the efficacy of FOLFIRI plus zib-aflibercept (AFL) after FTD/TPI plus BEV, including clinical results with plasma biomarker analyses...
March 1, 2024: Targeted Oncology
https://read.qxmd.com/read/38400671/phase-i-study-of-sapanisertib-cb-228-tak-228-mln0128-in-combination-with-ziv-aflibercept-in-patients-with-advanced-solid-tumors
#2
JOURNAL ARTICLE
Niamh Coleman, Bettzy Stephen, Siqing Fu, Daniel Karp, Vivek Subbiah, Jordi Rodon Ahnert, Sarina A Piha-Paul, John Wright, Senait N Fessahaye, Fengying Ouyang, Bulent Yilmaz, Funda Meric-Bernstam, Aung Naing
BACKGROUND: Sapanisertib is a potent ATP-competitive, dual inhibitor of mTORC1/2. Ziv-aflibercept is a recombinant fusion protein comprising human VEGF receptor extracellular domains fused to human immunoglobulin G1. HIF-1α inhibition in combination with anti-angiogenic therapy is a promising anti-tumor strategy. This Phase 1 dose-escalation/expansion study assessed safety/ tolerability of sapanisertib in combination with ziv-aflibercept in advanced solid tumors. METHODS: Fifty-five patients with heavily pre-treated advanced metastatic solid tumors resistant or refractory to standard treatment received treatment on a range of dose levels...
February 2024: Cancer Medicine
https://read.qxmd.com/read/38308362/comparison-of-antiangiogenic-agents-ranibizumab-aflibercept-bevacizumab-and-ziv-aflibercept-in-the-therapeutic-response-to-the-exudative-form-of-age-related-macular-degeneration-according-to-the-treat-and-extend-protocol-true-head-to-head-study
#3
JOURNAL ARTICLE
Tereza Kanadani, Neiffer Rabelo, Denise Takahashi, Lucas Magalhães, Michel Farah
PURPOSE: To evaluate the structural and functional changes in eyes with neovascular age related macular degeneration (nAMD) in a real-world setting, using Treat and Extend protocol (T&E), comparing four antiangiogenic agents. METHODS: Prospective, observational, case series study performed in 131 patients with the exudative form of nAMD. Patients were randomly assigned into four groups according to the antiangiogenic agent. During the first year, all eyes received at least 3 monthly intravitreal injections of antiangiogenic agents, and afterwards, were submitted to the T&E...
February 2, 2024: International Journal of Retina and Vitreous
https://read.qxmd.com/read/38236249/ziv-aflibercept-plus-pembrolizumab-in-patients-with-advanced-melanoma-resistant-to-anti-pd-1-treatment
#4
JOURNAL ARTICLE
Joanna Baginska, Allison Nau, Ilana Gomez Diaz, Anita Giobbie-Hurder, Jason Weirather, Juliana Vergara, Charlotte Abrecht, Margaret Hallisey, Jenna Dennis, Mariano Severgnini, Julia Huezo, Isabella Marciello, Osama Rahma, Michael Manos, Andrew S Brohl, Philippe L Bedard, Daniel J Renouf, Elad Sharon, Howard Streicher, Patrick A Ott, Elizabeth I Buchbinder, F Stephen Hodi
BACKGROUND: Vascular endothelial growth factor is associated with reduced immune response and impaired anti-tumor activity. Combining antiangiogenic agents with immune checkpoint inhibition can overcome this immune suppression and enhance treatment efficacy. METHODS: This study investigated the combination of ziv-aflibercept anti-angiogenic therapy with pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment. Baseline and on-treatment plasma and PBMC samples were analyzed by multiplex protein assay and mass cytometry, respectively...
January 18, 2024: Cancer Immunology, Immunotherapy: CII
https://read.qxmd.com/read/37743891/intravitreal-ziv-aflibercept-versus-bevacizumab-for-na%C3%A3-ve-central-retinal-vein-occlusion-with-macular-edema-an-interim-analysis-of-a-randomized-non-inferiority-trial
#5
JOURNAL ARTICLE
Suthasinee Sinawat, Suthasinee Hemanak, Kwanchanok Chanthowong, Supat Sinawat, Yosanan Yospaiboon
PURPOSE: To compare the efficacy of intravitreal ziv-aflibercept (IVZ) and bevacizumab (IVB) injections for the treatment of macular edema secondary to central retinal vein occlusion. METHODS: Participants were randomly assigned 1:1 to receive 3 monthly IVZ (1.25 mg/0.05 mL) or IVB (1.25 mg/0.05 mL) followed by the pro-re-nata protocol for persistent or recurrent macular edema. The primary outcomes were best-corrected visual acuity and central subfield thickness...
2023: Clinical Ophthalmology
https://read.qxmd.com/read/37181609/ziv-aflibercept-in-diabetic-macular-edema-relation-of-subfoveal-choroidal-thickness-with-visual-and-anatomical-outcomes
#6
JOURNAL ARTICLE
Siamak Moradian, Masoud Soheilian, Mahsan Asadi, Abdolreza Baghi, Hamid Safi, Seyed-Hossein Abtahi
PURPOSE: To evaluate the effects of intravitreal ziv-aflibercept injections (IVZ) on subfoveal choroidal thickness (SCT) as well as on central macular thickness (CMT) and on best corrected visual acuity (BCVA) changes in eyes with center-involved diabetic macular edema (CI-DME). METHODS: Fifty-seven eyes of 36 patients with CI-DME were included in this prospective interventional case series. Structural optical coherence tomography (OCT) and enhanced depth imaging OCT were performed at baseline followed by three monthly 1...
2023: Journal of Ophthalmic & Vision Research
https://read.qxmd.com/read/37128793/molecular-prognostic-factors-in-colorectal-cancer-5-year-follow-up
#7
JOURNAL ARTICLE
Alina Elena Ciobanu, Daniel Cristian Pîrvu, Cristina Maria Mărginean, Anda Lorena Dijmărescu, Adriana Estefa Muñoz-Groza, Cristian Meşină, Tudor Adrian Bălşeanu, Vlad Dumitru Băleanu, Tiberiu Ştefăniţă Ţenea-Cojan, Daniela Ciobanu
Colorectal cancer (CRC) is a frequently diagnosed and lethal disease. The risk of developing CRC is determined by environmental and genetic factors. Surgical treatment is the main curative modality for patients with CRC up to stage III. In recent years, a special place has been given to biological agents used as targeted therapy following the genetic analysis of the tumor: Bevacizumab (Avastin), Cetuximab (Erbitux), Ziv-aflibercept (Zaltrap). We present a study based on 46 colorectal tumor resection specimens from patients operated for CRC in the Surgery Departments of the Emergency County Clinical Hospital of Craiova, Romania...
2023: Romanian Journal of Morphology and Embryology
https://read.qxmd.com/read/37077223/effectiveness-of-the-use-of-three-dose-intravitreal-ziv-aflibercept-in-the-management-of-diabetic-macular-edema-in-a-real-life-setting
#8
JOURNAL ARTICLE
Fernando Munayco-Guillén, Miguel Angel Vazquez-Membrillo, Marlon Rafael Garcia-Roa, Jhony Alberto De La Cruz-Vargas, Herney Andrés García-Perdomo, Rafael Pichardo-Rodriguez
PURPOSE: It has been reported that intravitreal Ziv-aflibercept is a safe and effective drug for the treatment of diabetes macular edema (DME). The objective of this study was to evaluate in a real-life setting, the efficacy of intravitreal Ziv-aflibercept in the treatment of DME after the administration of three consecutive monthly doses. METHODS: A single arm, prospective cohort study. We included patients with DME who received three doses of intravitreal Ziv-aflibercept...
2023: Clinical Ophthalmology
https://read.qxmd.com/read/37007093/comparison-of-the-second-line-treatments-for-patients-with-small-cell-lung-cancer-sensitive-to-previous-platinum-based-chemotherapy-a-systematic-review-and-bayesian-network-analysis
#9
Hekai Shi, Nuojin Guo, Zeming Zhao, Ligang Liu, Tianyi Ni, Jinye Zhang, Yingjie Lu
OBJECTIVE: It remains unclear what the best second-line treatment is for patients with small-cell lung cancer sensitive to previous platinum-based chemotherapy. METHODS: We systematically screened randomized controlled trials from several online databases. The primary outcome was objective response rate (ORR), and the secondary outcomes were disease control rate (DCR), overall survival (OS), progression-free survival (PFS), and hematological complications graded 3 to 5...
2023: Frontiers in Oncology
https://read.qxmd.com/read/36825253/the-use-of-aflibercept-vegf-trap-in-mitigating-sulfur-mustard-induced-corneal-neovascularization-in-a-rabbit-model
#10
JOURNAL ARTICLE
Ariel Gore, Tamar Kadar, Maayan Cohen, Hila Gutman, Rellie Gez, Shlomit Dachir, Vered Horwitz
Sulfur mustard (SM)-induced ocular injury is characterized by an acute inflammatory response that may become chronic or enter a latent phase with delayed pathology. This study aimed to evaluate the efficacy of ziv-aflibercept and aflibercept in preventing and ameliorating corneal neovascularization (NV), respectively, following chemical eye exposure to SM vapor in a rabbit model. Chemical SM ocular insult was induced in the right eye of rabbits. A single application of ziv-aflibercept was administered 2 h or 9 days post-exposure...
2023: Toxicology Reports
https://read.qxmd.com/read/36395401/a-phase-ii-study-of-ziv-aflibercept-in-patients-with-advanced-extrapancreatic-neuroendocrine-tumors
#11
JOURNAL ARTICLE
Kimberly Perez, Matthew H Kulke, Nora K Horick, Eileen Regan, Christopher Graham, Samantha Scheutz, Danielle Stonely, Peter C Enzinger, Charles S Fuchs, Jill N Allen, Andrea C Enzinger, Jeffrey W Clark, Jennifer A Chan
OBJECTIVES: Neuroendocrine tumors (NETs) are characterized by their expression of vascular endothelial growth factor (VEGF). This trial investigated the activity of Ziv-aflibercept, a recombinant protein that binds to and inhibits the activity of VEGF, in patients with advanced NETs (NCT01782443). METHODS: A single-arm, phase II trial enrolling patients with advanced, progressive extrapancreatic NET. Patients were treated with Ziv-aflibercept 4 mg/kg intravenously on day 1 and 15 of a 28-day cycle; the starting dose was reduced to 2 mg/kg on days 1 and 15 of a 28-day cycle because of hypertension-related events...
August 1, 2022: Pancreas
https://read.qxmd.com/read/35857984/quantitative-assessment-of-silicone-oil-release-with-siliconized-and-silicone-oil-free-syringes-by-microflow-imaging-microscopy
#12
JOURNAL ARTICLE
Lydianne Lumack do Monte Agra, Natasha Ferreira Santos da Cruz, Vaida Linkuviene, John F Carpenter, Michel Eid Farah, Gustavo Barreto Melo, Maurício Maia
PURPOSE: Since particles are released in syringes during intravitreal injections, we assessed them quantitatively after agitating syringes commonly used for intravitreal injections. METHODS: With and without agitation, the SR 1-ml insulin, Becton-Dickinson Ultra-Fine 0.3-ml Short Needle with a half-unit scale, HSW Norm-Ject Tuberculin, and Becton-Di-ckinson 1-ml Luer Lok Tip were examined with buffer and bevacizumab, aflibercept, and ziv-aflibercept. Flow imaging microscopy was performed to assess the particle numbers, concentrations, morphology, and size distribution...
July 15, 2022: Arquivos Brasileiros de Oftalmologia
https://read.qxmd.com/read/35768859/switching-to-ziv-aflibercept-in-resistant-diabetic-macular-edema-non-responsive-to-ranibizumab-injection
#13
JOURNAL ARTICLE
Amin E Nawar, Tamer Wasfy, Heba M Shafik
BACKGROUND: Diabetic macular edema (DME) is a leading cause of visual loss in diabetic patients and is managed using multiple anti-vascular endothelial growth factor (VEGF) agents such as bevacizumab, ranibizumab and aflibercept. The present study evaluates effectiveness of intravitreal injection of ziv-aflibercept in resistant diabetic macular edema. METHODS: This is a prospective interventional study that was carried out on 59 eyes of 40 diabetic patients with diabetic macular edema resistant to three prior consecutive ranibizumab injections...
June 29, 2022: BMC Ophthalmology
https://read.qxmd.com/read/35590054/use-of-ziv-aflibercept-in-diabetic-macular-edema-in-a-ghanaian-population
#14
RANDOMIZED CONTROLLED TRIAL
Imoro Zeba Braimah, Winfried M Amoaku
AIM: To investigate the use of intravitreal ziv-aflibercept (IVZ) in Ghanaian patients with diabetic macular edema (DME). METHODS: A retrospective study of patients with DME, who had been treated with IVZ (1.25 mg/0.05 ml), as part of routine clinical practice, on pro re nata basis between 2016 and 2018 who had a minimum follow-up of 6 months was retrieved and analyzed. The primary outcome measure was change in best-corrected visual acuity (BCVA) at 6 months...
May 2022: Eye
https://read.qxmd.com/read/34228553/safety-review-of-anti-vegf-therapy-in-patients-with-myopic-choroidal-neovascularization
#15
JOURNAL ARTICLE
Danny S C Ng, Mary Ho, Lawrence P L Iu, Timothy Y Y Lai
INTRODUCTION: Anti-angiogenesis therapy with intravitreal anti-VEGF agents is now the standard-of-care treatment for myopic choroidal neovascularization (CNV). AREAS COVERED: We provide a critical review of the safety of all the anti-VEGF agents currently used for treating myopic CNV including ranibizumab, aflibercept, conbercept, bevacizumab and ziv-aflibercept. EXPERT OPINION: Anti-VEGF therapy for myopic CNV with the currently available anti-VEGF drugs generally have favorable safety outcomes in the short-term...
July 6, 2021: Expert Opinion on Drug Safety
https://read.qxmd.com/read/34153938/stability-study-over-time-of-clinical-solutions-of-ziv-aflibercept-prepared-in-infusion-bags-using-a-proper-combination-of-physicochemical-and-functional-strategies
#16
JOURNAL ARTICLE
Jesús Hermosilla, Raquel Pérez-Robles, Antonio Salmerón-García, Salvador Casares, Jose Cabeza, Natalia Navas
A range of biopharmaceutical products are used to target Vascular Endothelial Growth Factor (VEGF), including Eylea® (aflibercept, AFL) and Zaltrap® (ziv-aflibercept, ziv-AFL). The first is indicated for ophthalmological diseases such as neovascular (wet) age-related macular degeneration, while the second is used in the treatment of metastatic colorectal cancer. The stability of AFL in prefilled syringes has been widely studied; however, no research has yet been done on the stability of ziv-AFL in polyolefin infusion bags...
June 16, 2021: Journal of Pharmaceutical and Biomedical Analysis
https://read.qxmd.com/read/34123809/angiogenesis-inhibitors-in-small-cell-lung-cancer
#17
REVIEW
Agnese Montanino, Anna Manzo, Guido Carillio, Giuliano Palumbo, Giovanna Esposito, Vincenzo Sforza, Raffaele Costanzo, Claudia Sandomenico, Gerardo Botti, Maria C Piccirillo, Priscilla Cascetta, Giacomo Pascarella, Carmine La Manna, Nicola Normanno, Alessandro Morabito
Inhibition of angiogenesis has been demonstrated to be an efficacious strategy in treating several tumors. Vascular endothelial growth factor (VEGF) is the most important protein with proangiogenic functions and it is overexpressed in small cell lung cancer (SCLC). Bevacizumab, a monoclonal antibody directed against VEGF, showed a promising activity in combination with etoposide and cisplatin as first-line treatment of patients with extended stage (ES)-SCLC and two randomized studies confirmed that bevacizumab improved PFS, but failed to prolong OS...
2021: Frontiers in Oncology
https://read.qxmd.com/read/33890418/silicone-oil-free-syringes-siliconized-syringes-and-needles-quantitative-assessment-of-silicone-oil-release-with-drugs-used-for-intravitreal-injection
#18
JOURNAL ARTICLE
Gustavo Barreto Melo, Natasha Ferreira Santos da Cruz, Lydianne Lumack do Monte Agra, Geoffrey Guy Emerson, Luiz H Lima, Vaida Linkuviene, Maurício Maia, Michel Eid Farah, John F Carpenter, Eduardo Büchele Rodrigues, Christine Probst
PURPOSE: This study aimed to quantify the amount of silicone oil (SO) released across a variety of syringe and needle models routinely used for intravitreal injection. METHODS: The release of SO was assessed in eight models of syringes, two of which were reported to be 'SO-free', and eleven models of needles with unknown SO content. To evaluate SO release within the context of anti-VEGF therapeutics, syringes were evaluated using aflibercept, bevacizumab, buffer, ziv-aflibercept and formulation buffer...
April 22, 2021: Acta Ophthalmologica
https://read.qxmd.com/read/33782846/efficacy-of-intravitreal-ziv-aflibercept-in-patients-with-macular-edema-following-retinal-vein-occlusion-in-korle-bu-teaching-hospital-ghana-a-retrospective-case-series
#19
JOURNAL ARTICLE
Imoro Zeba Braimah, Kofi Agyabeng, Winfried M Amoaku
AIM: To evaluate the efficacy of ziv-aflibercept in Ghanaian patients with macular edema (ME) secondary to retinal vein occlusion (RVO). METHODOLOGY: In this retrospective study, the medical records of patients with ME secondary to RVO who had been treated with intravitreal ziv-aflibercept (IVZ) (1.25 mg/0.05 ml), as part of routine clinical practice, on pro re nata basis with a minimum follow-up of 6 months were retrieved and analyzed. The main outcome measures are mean change in best-corrected visual acuity (BCVA) and central subfield foveal thickness (CSFT) measured on optical coherence tomography from baseline to 12 months post-IVZ, and ocular and systemic safety...
March 29, 2021: International Ophthalmology
https://read.qxmd.com/read/33684428/analytical-comparability-assessment-on-glycosylation-of-ziv-aflibercept-and-the-biosimilar-candidate
#20
JOURNAL ARTICLE
Zhenduo Shen, Yanhong Wang, Huarong Xu, Qian Zhang, Chunjie Sha, Baiping Sun, Qing Li
Ziv-aflibercept (aflibercept) is a recombinant fusion protein which combines the portions of human vascular endothelial growth factor receptors extracellular domains fused to the Fc portion of human IgG1. It is a highly sialylated glycoprotein with 5 N-glycosylation sites. In this study, a comprehensive strategy for comparability study of the complex glycosylation was developed between aflibercept and the biosimilar candidate including the investigations on N-glycosylation sites, site occupancy, site-specific glycoforms, released glycans and sialic acids...
March 5, 2021: International Journal of Biological Macromolecules
keyword
keyword
66937
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.